Impact of the 340B Drug Pricing Program on Cancer Care Site and Spending in Medicare

Jeah Jung, Wendy Y. Xu, Yamini Kalidindi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To examine the impact of the 340B drug discount program on the site of cancer drug administration and cancer care spending in Medicare. Data Sources/Study Setting: 2010–2013 Medicare claims data for a random sample of Medicare Fee-for-Service beneficiaries with cancer. Study Design: We identified the 340B effect using variation in the availability of 340B hospitals across markets. We considered beneficiaries from markets that newly gained a 340B hospital during the study period (new 340B markets) as the treatment group. Beneficiaries in markets with no 340B hospital were the control group. We used a difference-in-differences approach with market fixed effects. Data Collection: Secondary data analysis. Principal Findings: The probability of a patient receiving cancer drug administration in hospital outpatient departments (HOPDs) versus physician offices increased 7.8 percentage points more in new 340B markets than in markets with no 340B hospital. Per-patient spending on other cancer care increased $1,162 more in new 340B markets than in markets with no 340B hospital. Conclusions: The 340B program shifted the site of cancer drug administration to HOPDs and increased spending on other cancer care. As the program expands, continuing assessment of its impact on service utilization and spending would be needed.

Original languageEnglish (US)
Pages (from-to)3528-3548
Number of pages21
JournalHealth Services Research
Volume53
Issue number5
DOIs
StatePublished - Oct 2018

Fingerprint

Medicare
Costs and Cost Analysis
Pharmaceutical Preparations
Neoplasms
Hospital Departments
Outpatients
Fee-for-Service Plans
Physicians' Offices
Information Storage and Retrieval
Control Groups

All Science Journal Classification (ASJC) codes

  • Health Policy

Cite this

Jung, Jeah ; Xu, Wendy Y. ; Kalidindi, Yamini. / Impact of the 340B Drug Pricing Program on Cancer Care Site and Spending in Medicare. In: Health Services Research. 2018 ; Vol. 53, No. 5. pp. 3528-3548.
@article{9e71a315c0404ad6bd10502dacced8f4,
title = "Impact of the 340B Drug Pricing Program on Cancer Care Site and Spending in Medicare",
abstract = "Objective: To examine the impact of the 340B drug discount program on the site of cancer drug administration and cancer care spending in Medicare. Data Sources/Study Setting: 2010–2013 Medicare claims data for a random sample of Medicare Fee-for-Service beneficiaries with cancer. Study Design: We identified the 340B effect using variation in the availability of 340B hospitals across markets. We considered beneficiaries from markets that newly gained a 340B hospital during the study period (new 340B markets) as the treatment group. Beneficiaries in markets with no 340B hospital were the control group. We used a difference-in-differences approach with market fixed effects. Data Collection: Secondary data analysis. Principal Findings: The probability of a patient receiving cancer drug administration in hospital outpatient departments (HOPDs) versus physician offices increased 7.8 percentage points more in new 340B markets than in markets with no 340B hospital. Per-patient spending on other cancer care increased $1,162 more in new 340B markets than in markets with no 340B hospital. Conclusions: The 340B program shifted the site of cancer drug administration to HOPDs and increased spending on other cancer care. As the program expands, continuing assessment of its impact on service utilization and spending would be needed.",
author = "Jeah Jung and Xu, {Wendy Y.} and Yamini Kalidindi",
year = "2018",
month = "10",
doi = "10.1111/1475-6773.12823",
language = "English (US)",
volume = "53",
pages = "3528--3548",
journal = "Health Services Research",
issn = "0017-9124",
publisher = "Wiley-Blackwell",
number = "5",

}

Impact of the 340B Drug Pricing Program on Cancer Care Site and Spending in Medicare. / Jung, Jeah; Xu, Wendy Y.; Kalidindi, Yamini.

In: Health Services Research, Vol. 53, No. 5, 10.2018, p. 3528-3548.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of the 340B Drug Pricing Program on Cancer Care Site and Spending in Medicare

AU - Jung, Jeah

AU - Xu, Wendy Y.

AU - Kalidindi, Yamini

PY - 2018/10

Y1 - 2018/10

N2 - Objective: To examine the impact of the 340B drug discount program on the site of cancer drug administration and cancer care spending in Medicare. Data Sources/Study Setting: 2010–2013 Medicare claims data for a random sample of Medicare Fee-for-Service beneficiaries with cancer. Study Design: We identified the 340B effect using variation in the availability of 340B hospitals across markets. We considered beneficiaries from markets that newly gained a 340B hospital during the study period (new 340B markets) as the treatment group. Beneficiaries in markets with no 340B hospital were the control group. We used a difference-in-differences approach with market fixed effects. Data Collection: Secondary data analysis. Principal Findings: The probability of a patient receiving cancer drug administration in hospital outpatient departments (HOPDs) versus physician offices increased 7.8 percentage points more in new 340B markets than in markets with no 340B hospital. Per-patient spending on other cancer care increased $1,162 more in new 340B markets than in markets with no 340B hospital. Conclusions: The 340B program shifted the site of cancer drug administration to HOPDs and increased spending on other cancer care. As the program expands, continuing assessment of its impact on service utilization and spending would be needed.

AB - Objective: To examine the impact of the 340B drug discount program on the site of cancer drug administration and cancer care spending in Medicare. Data Sources/Study Setting: 2010–2013 Medicare claims data for a random sample of Medicare Fee-for-Service beneficiaries with cancer. Study Design: We identified the 340B effect using variation in the availability of 340B hospitals across markets. We considered beneficiaries from markets that newly gained a 340B hospital during the study period (new 340B markets) as the treatment group. Beneficiaries in markets with no 340B hospital were the control group. We used a difference-in-differences approach with market fixed effects. Data Collection: Secondary data analysis. Principal Findings: The probability of a patient receiving cancer drug administration in hospital outpatient departments (HOPDs) versus physician offices increased 7.8 percentage points more in new 340B markets than in markets with no 340B hospital. Per-patient spending on other cancer care increased $1,162 more in new 340B markets than in markets with no 340B hospital. Conclusions: The 340B program shifted the site of cancer drug administration to HOPDs and increased spending on other cancer care. As the program expands, continuing assessment of its impact on service utilization and spending would be needed.

UR - http://www.scopus.com/inward/record.url?scp=85047761025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047761025&partnerID=8YFLogxK

U2 - 10.1111/1475-6773.12823

DO - 10.1111/1475-6773.12823

M3 - Article

C2 - 29355925

AN - SCOPUS:85047761025

VL - 53

SP - 3528

EP - 3548

JO - Health Services Research

JF - Health Services Research

SN - 0017-9124

IS - 5

ER -